The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study.
 
Josep M Llovet
Consulting or Advisory Role - AstraZeneca; Bayer; Boston Scientific; Bristol Myers Squibb; Eisai; Genentech; Glycotest; Ipsen; Iylon; Lilly; Merck; Mina Alpha Ltd; Nucleix; Omega Therapeutics; Roche
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Bayer
 
Masatoshi Kudo
Honoraria - Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Research Funding - Abbvie (Inst); Chugai/Roche; EA Pharma (Inst); Eisai (Inst); GE Healthcare; Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Philippe Merle
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; MSD; Roche
Research Funding - Ipsen
 
Tim Meyer
Consulting or Advisory Role - Bayer; Beigene; BTG; Eisai; Ipsen; MSD; Roche
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Abbott Laboratories; Abbvie; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Fujifilm; Incyte; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Ruocai Xu
No Relationships to Disclose
 
Julien Edeline
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Basilea; Bayer; BeiGene; Boston Scientific; Bristol-Myers Squibb; BTG; Eisai; Ipsen; Merck Serono; MSD; Roche; SERVIER; Taiho Oncology
Research Funding - Beigene (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Zhenggang Ren
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme; Roche
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; Eisai; Genentech/Roche; Ipsen; IQVIA; MSD; Ono Pharmaceutical; Roche
 
Peter R Galle
Honoraria - Adaptimmune; AstraZeneca/MedImmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Guerbet; Ipsen; Lilly; MSD; Roche/Genentech; Sirtex Medical
Consulting or Advisory Role - Adaptimmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech; Sirtex Medical
Speakers' Bureau - Bayer Schering Pharma; Ipsen; Lilly; Roche
Research Funding - Roche/Genentech
Travel, Accommodations, Expenses - Bayer Schering Pharma; Lilly; Sirtex Medical
 
Shuichi Kaneko
Consulting or Advisory Role - Bayer; Eisai; Lilly
Research Funding - AVI Pharma; Bayer; Eisai; Lilly; Otsuka; Pfizer; Sumitomo Dainippon Pharma; Takeda
Other Relationship - AVI Pharma; Bayer; Eisai; Lilly; Sumitomo Dainippon Pharma; Takeda
 
Hiromitsu Kumada
Employment - Toranomon Hospital
Other Relationship - Abbvie; Eisai; Gilead Sciences; Sumitomo Chemical; Sumitomo Dainippon Pharma
 
Shital Kamble
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Josephine M Norquist
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Kalgi Mody
Employment - Eisai; Eisai
Travel, Accommodations, Expenses - Eisai; Eisai
 
Leonid Dubrovsky
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Abby B. Siegel
Employment - Merck
Stock and Other Ownership Interests - Merck
Patents, Royalties, Other Intellectual Property - I have a patent pending related to a drug combination at Merck. I received 1$ (token) for this.
Travel, Accommodations, Expenses - Merck
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Hengrui Therapeutics; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Bayer